KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInterest Coverage RatioInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Royalty Pharma (RPRX) Return on Sales: 2020-2025

Historic Return on Sales for Royalty Pharma (RPRX) over the last 6 years, with Sep 2025 value amounting to 0.55%.

  • Royalty Pharma's Return on Sales fell 20.00% to 0.55% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.55%, marking a year-over-year decrease of 20.00%. This contributed to the annual value of 0.59% for FY2024, which is 13.00% down from last year.
  • As of Q3 2025, Royalty Pharma's Return on Sales stood at 0.55%, which was down 23.24% from 0.72% recorded in Q2 2025.
  • Royalty Pharma's Return on Sales' 5-year high stood at 0.87% during Q2 2021, with a 5-year trough of 0.10% in Q4 2022.
  • In the last 3 years, Royalty Pharma's Return on Sales had a median value of 0.55% in 2025 and averaged 0.52%.
  • In the last 5 years, Royalty Pharma's Return on Sales slumped by 71bps in 2021 and then spiked by 62bps in 2023.
  • Quarterly analysis of 5 years shows Royalty Pharma's Return on Sales stood at 0.54% in 2021, then slumped by 44bps to 0.10% in 2022, then soared by 62bps to 0.72% in 2023, then decreased by 13bps to 0.59% in 2024, then decreased by 20bps to 0.55% in 2025.
  • Its last three reported values are 0.55% in Q3 2025, 0.72% for Q2 2025, and 0.78% during Q1 2025.